Clinical Trials & Studies
University Hospitals Harrington Heart & Vascular Institute continues to build on a legacy of innovation that began over 150 years ago. Our team is forging medicine’s future by translating cardiovascular advances at the earliest stages of development into improved patient care.
Learn MoreTo learn more about heart and vascular clinical trials, call 216-844-3130
Our team of more than 70 cardiovascular faculty, fellows and staff manages over 140 active clinical trials and follows more than 3,500 patients. Our trials include first-in-human and Phase II-IV studies in cardiovascular medicine, interventional cardiology, electrophysiology, vascular surgery, endovascular therapies, heart failure, cardiac surgery and advanced cardiovascular imaging.
The following highlights just a few of our actively recruiting clinical trials. These and other University Hospitals Cleveland Medical Center advances are poised to benefit the lives of patients affected by heart and vascular diseases for generations to come.
The BODY-REAL Study
Clinical effectiveness of body fat distribution imaging in real-world practice
Studies to address risks for cardiovascular disease
A study to evaluate the safety of atrial fibrillation treatment
Continuous Glucose Monitoring Device Study
Patient Registry Sub-Study Consent: Feasibility and Clinical Utility of the Dexcom in CINEMA Program Patients
Evaluating metabolic mechanisms of Ertugliflozin in diabetes & heart failure
EMMED without diabetes
Evaluating Metabolic Mechanisms of Ertugliflozin in Non-Diabetes Heart Failure with Preserved Ejection Fraction
Renal Denervation (SPYRAL)
Clinical research study to evaluate the potential benefits of an investigative device-based intervention to help lower blood pressure
Vascular Innovation Unit (VIU)
The Vascular Innovation Unit (VIU) focuses on being the first to bring the latest limb salvage techniques to our patients before anywhere else. Innovative limb salvage clinical trials are underway at University Hospitals Cleveland Medical Center.